1050 Background: Despite standard anti-HER2 regimens with chemotherapy, therapeutic challenges persist in HER2-positive metastatic breast cancer (MBC). Inetetamab (anti-HER2 monoclonal antibody) and pyrotinib (tyrosine kinase inhibitor) demonstrate established efficacy in advanced disease. Utidelone, a novel epothilone analog, exhibits antitumor activity with a differentiated safety profile. This phase II study assessed the triplet combination in first- or second-line HER2-positive MBC. Methods: This multicenter single-arm phase II trial enrolled HER2-positive MBC patients for first- or second-line therapy. Patients who have previously used trastuzumab must meet the followings: for first-line treatment, neoadjuvant therapy was effective, and relapse occurred over 1 year after the end of adjuvant therapy; for second-line treatment, progressed in previous adjuvant/neoadjuvant therapy or progressed within 1 year of completion of trastuzumab therapy; disease progression occurred after 6 months of treatment with trastuzumab in advanced setting. Patients with stable brain metastases were enrolled with or without prior local treatment. ECOG PS 0-1, and measurable disease (RECIST v1.1). Eligible patients received inetetamab (8 mg/kg cycle 1, then 6 mg/kg, IV, day 1), pyrotinib (400 mg, PO, daily), and utidelone (30 mg/m², IV, days 1-5) every 21 days until progression or intolerance. Primary endpoint was investigator-assessed ORR. Secondary endpoints included PFS, OS, and safety. Results: By data cutoff (December 31, 2025), the recruitment has been completed. 94 patients were enrolled. Median treatment cycles were 11 (range 4-57). 56 (65.9%) and 29 (34.1%) patients were in first- and second-line settings, respectively. 85 patients were evaluable for response with 6 CR, 64 PR and 7 SD. The ORR was 82.4% (95% CI, 72.6%-89.8%). Median PFS was 13.1 months (95% CI, 10.420-15.780). Median OS was not reached. The OS rate of 12-month, 26-month and 35-month was 94.6% (95% CI, 89.5%-99.7%), 85.2% (95% CI, 76.6%-93.8%) and 78.5% (95% CI, 67.7%-89.3%), respectively. Predominant Grade ≥3 TRAEs were diarrhea (28.2%) and peripheral neuropathy (4.7%). Other Grade ≥3 TRAEs included nausea (3.5%), transaminitis (2.4%) and neutropenia (1.2%). Treatment discontinuations due to TRAEs occurred in 6 patients (6.6%). No treatment-related deaths occurred. Conclusions: The regimen demonstrated clinically meaningful activity of this triplet regimen for the first/second-line treatment of HER2-positive MBC, evidenced by high ORR (82.4%), durable median PFS (13.1 months), with encouraging 35-month OS rate (78.5%). Predominant toxicities (diarrhea, neuropathy) were controllable through supportive measures and dose adjustments. These data support phase III evaluation of this combination strategy.
Cao et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: